KEYNOTE-181

NCT02564263 📎

Regimen

Experimental
pembrolizumab
Control
investigator-choice chemotherapy (paclitaxel, docetaxel, or irinotecan)

Population

Advanced or metastatic esophageal cancer (squamous or adenocarcinoma) progressed after one prior therapy

Key finding

CPS>=10 mOS 9.3 vs 6.7 mo (HR 0.69, 95% CI 0.52-0.93, p=0.0074); SCC mOS 8.2 vs 7.1 mo (HR 0.78); all-comer OS miss (HR 0.89, p=0.056)

Source: PMID 33026938

Timeline

    Guideline citations

    • NCCN ESOPHAGEAL (p.66)